Circulating Ceramide: A New Cardiometabolic Biomarker in Patients With Comorbid Acute Coronary Syndrome and Type 2 Diabetes Mellitus
AimsThis study investigated the association of circulating ceramides in patients with comorbid acute coronary syndrome and type 2 diabetes mellitus (ACS-DM).MethodsA total of 761 patients with coronary heart disease who were admitted to the Department of Cardiology at the Chinese PLA General Hospita...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-09-01
|
| Series: | Frontiers in Physiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fphys.2020.01104/full |
| _version_ | 1828838246803570688 |
|---|---|
| author | Ruihua Cao Zhiyi Fang Sulei Li Mengqi Xu Jibin Zhang Dong Han Wenchao Hu Liqiu Yan Yabin Wang Li Fan Feng Cao |
| author_facet | Ruihua Cao Zhiyi Fang Sulei Li Mengqi Xu Jibin Zhang Dong Han Wenchao Hu Liqiu Yan Yabin Wang Li Fan Feng Cao |
| author_sort | Ruihua Cao |
| collection | DOAJ |
| description | AimsThis study investigated the association of circulating ceramides in patients with comorbid acute coronary syndrome and type 2 diabetes mellitus (ACS-DM).MethodsA total of 761 patients with coronary heart disease who were admitted to the Department of Cardiology at the Chinese PLA General Hospital from March to August 2018 were enrolled in this study. Of these 761 patients, 282 were diagnosed with acute coronary syndrome (ACS). We selected 65 patients with ACS-DM (ACS-DM group; mean age 64.88 years; 38 men) and 65 patients with ACS but without any comorbidities (ACS group; mean age 64.68 years; 38 men); the two groups were matched by age and sex. We determined four circulating ceramides in 130 plasma samples: Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/24:1), and Cer(d18:1/24:0). The ceramides in plasma samples from patients with ACS and those from patients with ACS-DM were compared. Pearson correlation coefficients between individual ceramides and traditional cardiovascular risk factors for the whole study population were calculated. Multiple logistic regression models were used to evaluate the relativity between the ceramide and ACS-DM.ResultsCompared with the ACS group, the levels of Cer(d18:1/16:0), Cer(d18:1/18:0), and Cer(d18:1/24:1) and their ratios to Cer(d18:1/24:0) were higher in the ACS-DM group and Cer(d18:1/24:0) was lower in the ACS-DM group (P < 0.05). Correlation analysis demonstrated mild-to-moderate correlations of ceramide and traditional cardiovascular risk factors. There were relatively strong correlations of Cer(d18:1/18:0) and Cer(d18:1/24:1) with C-reactive protein, blood lipids, fasting blood glucose, and glycated hemoglobin A1c. In multiple logistic regression models, Cer(d18:1/18:0) [odds ratio (OR) 2.396; 95% confidence interval (CI) 1.103–5.205; P = 0.027], Cer(d18:1/24:1) (OR 2.826; 95% CI 1.158–6.896; P = 0.023), Cer(d18:1/18:0)/Cer(d18:1/24:0) (OR 2.242; 95% CI 1.103–4.555; P = 0.026), and Cer(d18:1/24:1)/Cer(d18:1/24:0) (OR 2.673; 95% CI 1.225–5.836; P = 0.014) were positively correlated with ACS-DM, and Cer(d18:1/24:0) (OR 0.200; 95% CI 0.051–0.778; P = 0.020) was negatively correlated with ACS-DM.ConclusionCirculating ceramides are positively correlated with the risk of ACS-DM comorbidity. These results give a new insight into the pathogenesis of ACS-DM comorbidity and could provide new options for risk estimation. |
| first_indexed | 2024-12-12T18:58:37Z |
| format | Article |
| id | doaj.art-980dd4e005d948d7a32c2bc0a91d8852 |
| institution | Directory Open Access Journal |
| issn | 1664-042X |
| language | English |
| last_indexed | 2024-12-12T18:58:37Z |
| publishDate | 2020-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Physiology |
| spelling | doaj.art-980dd4e005d948d7a32c2bc0a91d88522022-12-22T00:15:10ZengFrontiers Media S.A.Frontiers in Physiology1664-042X2020-09-011110.3389/fphys.2020.01104567967Circulating Ceramide: A New Cardiometabolic Biomarker in Patients With Comorbid Acute Coronary Syndrome and Type 2 Diabetes MellitusRuihua Cao0Zhiyi Fang1Sulei Li2Mengqi Xu3Jibin Zhang4Dong Han5Wenchao Hu6Liqiu Yan7Yabin Wang8Li Fan9Feng Cao10Department of Cardiology, The Second Medical Centre, Chinese PLA General Hospital, National Clinical Research Center for Geriatric Diseases, Beijing, ChinaThe Second Medical Centre, Chinese PLA General Hospital, National Clinical Research Center for Geriatric Diseases, Beijing, ChinaDepartment of Cardiology, The Second Medical Centre, Chinese PLA General Hospital, National Clinical Research Center for Geriatric Diseases, Beijing, ChinaDepartment of Cardiology, The Second Medical Centre, Chinese PLA General Hospital, National Clinical Research Center for Geriatric Diseases, Beijing, ChinaThe Second Medical Centre, Chinese PLA General Hospital, National Clinical Research Center for Geriatric Diseases, Beijing, ChinaDepartment of Cardiology, The Second Medical Centre, Chinese PLA General Hospital, National Clinical Research Center for Geriatric Diseases, Beijing, ChinaThe Second Medical Centre, Chinese PLA General Hospital, National Clinical Research Center for Geriatric Diseases, Beijing, ChinaThe Second Medical Centre, Chinese PLA General Hospital, National Clinical Research Center for Geriatric Diseases, Beijing, ChinaDepartment of Cardiology, The Second Medical Centre, Chinese PLA General Hospital, National Clinical Research Center for Geriatric Diseases, Beijing, ChinaDepartment of Cardiology, The Second Medical Centre, Chinese PLA General Hospital, National Clinical Research Center for Geriatric Diseases, Beijing, ChinaThe Second Medical Centre, Chinese PLA General Hospital, National Clinical Research Center for Geriatric Diseases, Beijing, ChinaAimsThis study investigated the association of circulating ceramides in patients with comorbid acute coronary syndrome and type 2 diabetes mellitus (ACS-DM).MethodsA total of 761 patients with coronary heart disease who were admitted to the Department of Cardiology at the Chinese PLA General Hospital from March to August 2018 were enrolled in this study. Of these 761 patients, 282 were diagnosed with acute coronary syndrome (ACS). We selected 65 patients with ACS-DM (ACS-DM group; mean age 64.88 years; 38 men) and 65 patients with ACS but without any comorbidities (ACS group; mean age 64.68 years; 38 men); the two groups were matched by age and sex. We determined four circulating ceramides in 130 plasma samples: Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/24:1), and Cer(d18:1/24:0). The ceramides in plasma samples from patients with ACS and those from patients with ACS-DM were compared. Pearson correlation coefficients between individual ceramides and traditional cardiovascular risk factors for the whole study population were calculated. Multiple logistic regression models were used to evaluate the relativity between the ceramide and ACS-DM.ResultsCompared with the ACS group, the levels of Cer(d18:1/16:0), Cer(d18:1/18:0), and Cer(d18:1/24:1) and their ratios to Cer(d18:1/24:0) were higher in the ACS-DM group and Cer(d18:1/24:0) was lower in the ACS-DM group (P < 0.05). Correlation analysis demonstrated mild-to-moderate correlations of ceramide and traditional cardiovascular risk factors. There were relatively strong correlations of Cer(d18:1/18:0) and Cer(d18:1/24:1) with C-reactive protein, blood lipids, fasting blood glucose, and glycated hemoglobin A1c. In multiple logistic regression models, Cer(d18:1/18:0) [odds ratio (OR) 2.396; 95% confidence interval (CI) 1.103–5.205; P = 0.027], Cer(d18:1/24:1) (OR 2.826; 95% CI 1.158–6.896; P = 0.023), Cer(d18:1/18:0)/Cer(d18:1/24:0) (OR 2.242; 95% CI 1.103–4.555; P = 0.026), and Cer(d18:1/24:1)/Cer(d18:1/24:0) (OR 2.673; 95% CI 1.225–5.836; P = 0.014) were positively correlated with ACS-DM, and Cer(d18:1/24:0) (OR 0.200; 95% CI 0.051–0.778; P = 0.020) was negatively correlated with ACS-DM.ConclusionCirculating ceramides are positively correlated with the risk of ACS-DM comorbidity. These results give a new insight into the pathogenesis of ACS-DM comorbidity and could provide new options for risk estimation.https://www.frontiersin.org/article/10.3389/fphys.2020.01104/fullceramideacute coronary syndrome with type 2 diabetes mellituscomorbiditycardiometabolic diseasesrisk factors |
| spellingShingle | Ruihua Cao Zhiyi Fang Sulei Li Mengqi Xu Jibin Zhang Dong Han Wenchao Hu Liqiu Yan Yabin Wang Li Fan Feng Cao Circulating Ceramide: A New Cardiometabolic Biomarker in Patients With Comorbid Acute Coronary Syndrome and Type 2 Diabetes Mellitus Frontiers in Physiology ceramide acute coronary syndrome with type 2 diabetes mellitus comorbidity cardiometabolic diseases risk factors |
| title | Circulating Ceramide: A New Cardiometabolic Biomarker in Patients With Comorbid Acute Coronary Syndrome and Type 2 Diabetes Mellitus |
| title_full | Circulating Ceramide: A New Cardiometabolic Biomarker in Patients With Comorbid Acute Coronary Syndrome and Type 2 Diabetes Mellitus |
| title_fullStr | Circulating Ceramide: A New Cardiometabolic Biomarker in Patients With Comorbid Acute Coronary Syndrome and Type 2 Diabetes Mellitus |
| title_full_unstemmed | Circulating Ceramide: A New Cardiometabolic Biomarker in Patients With Comorbid Acute Coronary Syndrome and Type 2 Diabetes Mellitus |
| title_short | Circulating Ceramide: A New Cardiometabolic Biomarker in Patients With Comorbid Acute Coronary Syndrome and Type 2 Diabetes Mellitus |
| title_sort | circulating ceramide a new cardiometabolic biomarker in patients with comorbid acute coronary syndrome and type 2 diabetes mellitus |
| topic | ceramide acute coronary syndrome with type 2 diabetes mellitus comorbidity cardiometabolic diseases risk factors |
| url | https://www.frontiersin.org/article/10.3389/fphys.2020.01104/full |
| work_keys_str_mv | AT ruihuacao circulatingceramideanewcardiometabolicbiomarkerinpatientswithcomorbidacutecoronarysyndromeandtype2diabetesmellitus AT zhiyifang circulatingceramideanewcardiometabolicbiomarkerinpatientswithcomorbidacutecoronarysyndromeandtype2diabetesmellitus AT suleili circulatingceramideanewcardiometabolicbiomarkerinpatientswithcomorbidacutecoronarysyndromeandtype2diabetesmellitus AT mengqixu circulatingceramideanewcardiometabolicbiomarkerinpatientswithcomorbidacutecoronarysyndromeandtype2diabetesmellitus AT jibinzhang circulatingceramideanewcardiometabolicbiomarkerinpatientswithcomorbidacutecoronarysyndromeandtype2diabetesmellitus AT donghan circulatingceramideanewcardiometabolicbiomarkerinpatientswithcomorbidacutecoronarysyndromeandtype2diabetesmellitus AT wenchaohu circulatingceramideanewcardiometabolicbiomarkerinpatientswithcomorbidacutecoronarysyndromeandtype2diabetesmellitus AT liqiuyan circulatingceramideanewcardiometabolicbiomarkerinpatientswithcomorbidacutecoronarysyndromeandtype2diabetesmellitus AT yabinwang circulatingceramideanewcardiometabolicbiomarkerinpatientswithcomorbidacutecoronarysyndromeandtype2diabetesmellitus AT lifan circulatingceramideanewcardiometabolicbiomarkerinpatientswithcomorbidacutecoronarysyndromeandtype2diabetesmellitus AT fengcao circulatingceramideanewcardiometabolicbiomarkerinpatientswithcomorbidacutecoronarysyndromeandtype2diabetesmellitus |